Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy
- 86 Downloads
To determine whether participants in the behavior enhances drug reduction of incontinence (BE-DRI) trial experienced reduction in the frequency of nocturia and/or nocturnal leakage during treatment with antimuscarinic phamacotherapy with or without additional behavioral therapy. We analyzed urinary diary data relating to nocturia and nocturnal incontinence before and after 8 weeks of study treatment in the BE-DRI trial, in which patients were randomly assigned to receive drug therapy with tolterodine tartrate extended-release capsules 4 mg alone or in combination with behavioral training. Chi-square tests assessed whether nocturia and nocturnal incontinence prevalence varied by treatment arm and paired t tests assessed the change in mean frequency of nocturia and nocturnal leakage. Among 305 women, 210 (69%) had an average of at least one nocturia episode at baseline. There were small but statistically significant differences (p < 0.001) in mean nocturia frequency and nocturnal incontinence frequency with both treatments after 8 weeks, but no significant difference between study treatment groups. Among these urge incontinent women, tolterodine with or without supervised behavioral therapy had little impact on either nocturic frequency or nocturnal incontinence.
KeywordsLower urinary tract Nocturia Antimuscarinic therapy Behavioral therapy Urge incontinence
Supported by cooperative agreements (U01 DK58225, U01 DK58229, U01 DK58234, U01 DK58231, U01 DK60379, U01 DK60380, U01 DK60393, U01 DK60395, U01 DK60397, and U01 DK60401) with the National Institute of Diabetes and Digestive and Kidney Diseases and by the National Institute of Child Health and Human Development and Office of Research in Women’s Health of the National Institutes of Health.
Conflicts of interest
MP FitzGerald has received research funding from and has provided consultation to Pfizer Inc and Astellas. Dr Lemack is lecturer for Astellas, Allergan, Pfizer, Novartis, and Indevus, has received research funding from Allergan, and has provided consultation to Allergan, Pfizer, and Novartis.
- 11.Burgio KL, Kraus SR, Menefee S, Borello-France D, Corton M, Johnson HW, Mallett V, Norton P, FitzGerald MP, Dandreo KJ, Richter HE, Rozanski T, Albo M, Zyczynski HM, Lemack GE, Chai TC, Khandwala S, Baker J, Brubaker L, Stoddard AM, Goode PS, Nielsen-Omeis B, Nager C, Kenton K, Tennstedt SL, Kusek JW, Chang TD, Nyberg LM, Steers W for the Urinary Incontinence Treatment Network. (2008) Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med 149:161–169Google Scholar